[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 64 pages | ID: G035A9AB2A55EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Drugs In Development, 2022, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape.

Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 3, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gastroenteritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastroenteritis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastroenteritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastroenteritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastroenteritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastroenteritis (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastroenteritis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastroenteritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Gastroenteritis - Overview
Gastroenteritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gastroenteritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastroenteritis - Companies Involved in Therapeutics Development
Allakos Inc
Beijing Kangleweishi Biotechnology Co Ltd
Blue Lake Biotechnology Inc
Bristol-Myers Squibb Co
Chongqing Zhifei Biological Products Co Ltd
Cocrystal Pharma Inc
Kyowa Kirin Co Ltd
Lanzhou Institute of Biological Products Co Ltd
Medicago Inc
Novo Medi Sciences Pvt Ltd
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Gastroenteritis - Drug Profiles
Antibodies for Gastroenteritis - Drug Profile
Product Description
Mechanism Of Action
benralizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
BLB-300 - Drug Profile
Product Description
Mechanism Of Action
cendakimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
dupilumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
HIL-214 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lirentelimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
norovirus (polyvalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
norovirus [strains GI.1 + GII.4] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Norovirus Gastroenteritis - Drug Profile
Product Description
Mechanism Of Action
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
rotavirus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
Gastroenteritis - Dormant Projects
Gastroenteritis - Discontinued Products
Gastroenteritis - Product Development Milestones
Featured News & Press Releases
Mar 30, 2021: Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
Nov 12, 2019: RedHill Biopharma announces publication of RHB-102 gastroenteritis phase 3 study results in JAMA
Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)
Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestinal diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
Mar 27, 2018: RedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting
Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
Jun 14, 2017: RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis
Apr 19, 2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D
Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA
Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda
Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results
Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Gastroenteritis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Gastroenteritis - Pipeline by Allakos Inc, 2022
Gastroenteritis - Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022
Gastroenteritis - Pipeline by Blue Lake Biotechnology Inc, 2022
Gastroenteritis - Pipeline by Bristol-Myers Squibb Co, 2022
Gastroenteritis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Gastroenteritis - Pipeline by Cocrystal Pharma Inc, 2022
Gastroenteritis - Pipeline by Kyowa Kirin Co Ltd, 2022
Gastroenteritis - Pipeline by Lanzhou Institute of Biological Products Co Ltd, 2022
Gastroenteritis - Pipeline by Medicago Inc, 2022
Gastroenteritis - Pipeline by Novo Medi Sciences Pvt Ltd, 2022
Gastroenteritis - Pipeline by RedHill Biopharma Ltd, 2022
Gastroenteritis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Gastroenteritis - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Gastroenteritis - Dormant Projects, 2022
Gastroenteritis - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Gastroenteritis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications